journal article·2025-03-26Open access

Probing the Role of Lipid Nanoparticle Elasticity on mRNA Delivery to the Placenta

Hannah C. Safford, Cecilia F. Shuler, Hannah C. Geisler, Ajay S. Thatte, Kelsey L. Swingle, Emily L. Han, Amanda M. Murray, Alex G. Hamilton, Hannah M. Yamagata, Michael J. Mitchell

Nano Letters· Volume 25· Issue 12

Abstract

It is well established that the physicochemical properties of lipid nanoparticles (LNPs) can govern their interactions with various biological barriers. One property hypothesized to influence nanoparticle-cell interactions is elasticity. Here, we formulate LNPs with naturally occurring cholesterol analogs to tune LNP elasticity and study its role on mRNA delivery to the placenta. LNP elasticity was measured via atomic force microscopy where these LNPs exhibited Young's moduli ranging from 71.0 ± 26.2 to 411.4 ± 145.7 kPa. In vitro screening of these LNPs in placental trophoblasts showed that stiffer LNPs improved LNP uptake and mRNA delivery compared with softer LNPs. Following intravenous administration to pregnant mice, the stiffer LNPs incorporating β-sitosterol enhanced placental and reduced liver mRNA delivery compared with softer LNPs containing only cholesterol. These results demonstrate the ability of stiffer LNPs to promote placental mRNA delivery and highlight the potential of tuning LNP elasticity to improve LNP-mediated mRNA delivery to organs of interest.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering

University of Pennsylvania

Department of Biophysics

Penn Institute for RNA Innovation, Perelman School of Medicine

Abramson Cancer Center, Perelman School of Medicine

Funding

National Science Foundation Graduate Research Fellowship Program · American Cancer Society · Division of Chemical, Bioengineering, Environmental, and Transport Systems · Burroughs Wellcome Fund · National Institutes of Health

References (48)

Show source-provided references
1. 10.1016/j.matt.2020.09.02010.1016/j.matt.2020.09.020 ↗
2. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
3. 10.1371/journal.pbio.300210510.1371/journal.pbio.3002105 ↗
4. 10.1016/j.molmed.2021.03.00310.1016/j.molmed.2021.03.003 ↗
5. 10.1002/smll.20230356810.1002/smll.202303568 ↗
6. 10.1016/j.jconrel.2024.05.03610.1016/j.jconrel.2024.05.036 ↗
7. 10.1021/jacs.2c1289310.1021/jacs.2c12893 ↗
8. 10.1016/j.bioactmat.2023.11.01410.1016/j.bioactmat.2023.11.014 ↗
9. 10.1073/pnas.230781012110.1073/pnas.2307810121 ↗
10. 10.1038/s41586-024-08291-210.1038/s41586-024-08291-2 ↗
11. 10.1038/s44222-023-00040-w10.1038/s44222-023-00040-w ↗
12. 10.1002/smll.20230085210.1002/smll.202300852 ↗
13. 10.1016/j.addr.2020.09.00610.1016/j.addr.2020.09.006 ↗
14. 10.1038/s41572-023-00417-610.1038/s41572-023-00417-6 ↗
15. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
16. 10.1021/acs.nanolett.0c0138610.1021/acs.nanolett.0c01386 ↗
17. 10.1016/j.jconrel.2021.10.03110.1016/j.jconrel.2021.10.031 ↗
18. 10.1002/adma.20231202610.1002/adma.202312026 ↗
19. 10.1016/j.scitotenv.2024.17224010.1016/j.scitotenv.2024.172240 ↗
20. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
21. 10.1016/j.jconrel.2019.12.00310.1016/j.jconrel.2019.12.003 ↗
22. 10.1126/sciadv.aaz431610.1126/sciadv.aaz4316 ↗
23. 10.1073/pnas.210482611810.1073/pnas.2104826118 ↗
24. 10.1038/s41467-017-02588-910.1038/s41467-017-02588-9 ↗
25. 10.1016/j.apsb.2019.02.01010.1016/j.apsb.2019.02.010 ↗
26. 10.1002/smll.20220307010.1002/smll.202203070 ↗
27. 10.1002/mabi.20190010510.1002/mabi.201900105 ↗
28. 10.1002/anie.20201392710.1002/anie.202013927 ↗
29. 10.1021/acsnano.2c1190410.1021/acsnano.2c11904 ↗
30. 10.1016/j.xphs.2022.11.02610.1016/j.xphs.2022.11.026 ↗
31. 10.1016/j.ces.2024.12069310.1016/j.ces.2024.120693 ↗
32. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
33. 10.1039/D0BM01947J10.1039/D0BM01947J ↗
34. 10.1021/jacs.9b0392710.1021/jacs.9b03927 ↗
35. 10.1021/la702382d10.1021/la702382d ↗
36. 10.1021/acs.analchem.9b0025010.1021/acs.analchem.9b00250 ↗
37. 10.1021/bm049941k10.1021/bm049941k ↗
38. 10.1038/s41467-022-33157-410.1038/s41467-022-33157-4 ↗
39. 10.1016/j.bbamem.2004.05.00610.1016/j.bbamem.2004.05.006 ↗
40. 10.1016/j.bbamem.2014.01.00710.1016/j.bbamem.2014.01.007 ↗
41. 10.1021/acs.nanolett.3c0257310.1021/acs.nanolett.3c02573 ↗
42. 10.1016/j.jconrel.2015.08.00710.1016/j.jconrel.2015.08.007 ↗
43. 10.1007/s11095-022-03166-510.1007/s11095-022-03166-5 ↗
44. Omo-Lamai, S.; Wang, Y.; Patel, M. N.; Essien, E.O.; Shen, M.; Majumdar, A.; Espy, C.; Wu, J.; Channer, B.; Tobin, M.; Murali, S.; Papp, T. E.; Maheshwari, R.; Wang, L.; Chase, L. S.; Zamora, M. Z.; Arral, M. L.; Marcos-Contreras, O. A.; Myerson, J. W.; Hunter, C. A.; Tsourkas, A.; Muzykantov, V.; Brodsky, I.; Shin, S.; Whitehead, K. A.; Gaskill, P.; Discher, D.; Parhiz, H.; Brenner, J. S. Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects. BioRxiv, April 18, 2024. 10.1101/2024.04.16.589801. Accessed 2025-01-20.10.1101/2024.04.16.589801 ↗
45. 10.1016/j.biomaterials.2016.09.00610.1016/j.biomaterials.2016.09.006 ↗
46. 10.1016/j.intimp.2021.10759810.1016/j.intimp.2021.107598 ↗
47. 10.3390/pharmaceutics1606077110.3390/pharmaceutics16060771 ↗
48. 10.1002/btm2.1055610.1002/btm2.10556 ↗